Raj is a venture partner and the president and CEO of Rectify Pharmaceuticals. Previously he co-founded and was chief scientific officer of Disarm Therapeutics until its sale to Eli Lilly in 2020, and was CSO of Padlock Therapeutics until its sale to BMS in 2016. Before that Raj was president and chief executive officer of Euclises Pharmaceuticals and senior vice president of Deciphera Pharmaceuticals. Prior to that, he was senior vice president of Jubilant Drug Discovery & Development. Raj spent 14 years in positions of increasing responsibility with Pfizer Global R&D and legacy Pharmacia and Searle companies. He has led multiple discovery & early clinical development teams that have advanced eight candidates into clinical trials for refractory cancers, rheumatoid arthritis, diabetic nephropathy, COPD, and pain.